Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DNTH Dianthus Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: DNTH
Price (delayed)
$19
Market cap
$611.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.89
Enterprise value
$602.32M
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused
Highlights
The revenue has soared by 102% YoY and by 4.6% from the previous quarter
The gross profit has surged by 102% year-on-year and by 4.6% since the previous quarter
DNTH's debt has soared by 181% year-on-year but it is down by 6% since the previous quarter
The EPS has soared by 64% YoY but it fell by 13% QoQ
Dianthus Therapeutics's net income has shrunk by 101% YoY and by 19% QoQ
DNTH's equity is down by 12% YoY and by 7% QoQ
Key stats
What are the main financial stats of DNTH
Market
Valuations
Earnings
Shares outstanding
32.16M
Market cap
$611.04M
Enterprise value
$602.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
104.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
92.32
Revenue
$6.52M
Gross profit
$6.52M
Operating income
-$117.2M
Net income
-$100.73M
EBIT
-$100.73M
EBITDA
-$100.29M
Free cash flow
-$90.97M
Per share
Balance sheet
Liquidity
EPS
-$2.89
EPS diluted
-$2.89
Free cash flow per share
-$2.54
Book value per share
$10.23
Revenue per share
$0.18
TBVPS
$9.74
Total assets
$348.58M
Total liabilities
$19.97M
Debt
$1.4M
Equity
$328.61M
Working capital
$254.05M
Debt to equity
0
Current ratio
15.99
Quick ratio
15.59
Net debt/EBITDA
0.09
Margins
Efficiency
Dividend
EBITDA margin
-1,537.3%
Gross margin
100%
Net margin
-1,544%
Operating margin
-1,796.4%
Return on assets
-27.9%
Return on equity
-29.3%
Return on invested capital
-40%
Return on capital employed
-30.4%
Return on sales
-1,544%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNTH stock price
How has the Dianthus Therapeutics stock price performed over time
Intraday
-1.4%
1 week
0.85%
1 month
-2.56%
1 year
-25.37%
YTD
-12.84%
QTD
4.74%
Financial performance
How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$6.52M
Gross profit
$6.52M
Operating income
-$117.2M
Net income
-$100.73M
Gross margin
100%
Net margin
-1,544%
The revenue has soared by 102% YoY and by 4.6% from the previous quarter
The gross profit has surged by 102% year-on-year and by 4.6% since the previous quarter
Dianthus Therapeutics's net income has shrunk by 101% YoY and by 19% QoQ
The operating income has plunged by 101% YoY and by 15% from the previous quarter
Price vs fundamentals
How does DNTH's price correlate with its fundamentals
Growth
What is Dianthus Therapeutics's growth rate over time
Valuation
What is Dianthus Therapeutics stock price valuation
P/E
N/A
P/B
1.86
P/S
104.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
92.32
The EPS has soared by 64% YoY but it fell by 13% QoQ
DNTH's equity is down by 12% YoY and by 7% QoQ
The stock's price to book (P/B) is 11% more than its 5-year quarterly average of 1.7 but 6% less than its last 4 quarters average of 2.0
The revenue has soared by 102% YoY and by 4.6% from the previous quarter
DNTH's P/S is 30% below its last 4 quarters average of 151.4
Efficiency
How efficient is Dianthus Therapeutics business performance
DNTH's return on invested capital has surged by 77% year-on-year and by 14% since the previous quarter
The ROE has decreased by 23% QoQ and by 16% YoY
DNTH's return on assets is down by 21% since the previous quarter and by 16% year-on-year
The ROS fell by 13% QoQ
Dividends
What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNTH.
Financial health
How did Dianthus Therapeutics financials performed over time
The company's total liabilities has surged by 104% YoY but it fell by 7% QoQ
Dianthus Therapeutics's quick ratio has shrunk by 63% YoY but it has increased by 4.2% QoQ
DNTH's debt is 100% smaller than its equity
DNTH's debt has soared by 181% year-on-year but it is down by 6% since the previous quarter
DNTH's equity is down by 12% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.